Zanubrutinib and Venetoclax in CLL (ZANU-VEN) (NCT05168930)
A Phase 2 Trial of Zanubrutinib and Venetoclax in Previously Treated CLL/SLL Patients
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Who can join: Review the eligibility criteria below.
Location: New England Cancer Specialists — Scarborough, Maine
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- New England Cancer Specialists — Scarborough, Maine
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- South Shore Hospital — South Weymouth, Massachusetts
📞 Contact the Study Coordinator
Phone: (207) 303-3429
Email: collip@newecs.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia (CLL)
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) — Stanford, California
- Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax — Basking Ridge, New Jersey
- A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies — New York, New York
- Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL — Stamford, Connecticut
- A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) — Houston, Texas
- Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib — Bethesda, Maryland
Explore by condition: All Chronic Lymphocytic Leukemia (CLL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.